Deflazacort: Difference between revisions

	WikiDoc Resources for Deflazacort
Articles
Most recent articles on Deflazacort Most cited articles on Deflazacort Review articles on Deflazacort Articles on Deflazacort in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Deflazacort Images of Deflazacort Photos of Deflazacort Podcasts & MP3s on Deflazacort Videos on Deflazacort
Evidence Based Medicine
Cochrane Collaboration on Deflazacort Bandolier on Deflazacort TRIP on Deflazacort
Clinical Trials
Ongoing Trials on Deflazacort at Clinical Trials.gov Trial results on Deflazacort Clinical Trials on Deflazacort at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Deflazacort NICE Guidance on Deflazacort NHS PRODIGY Guidance FDA on Deflazacort CDC on Deflazacort
Books
Books on Deflazacort
News
Deflazacort in the news Be alerted to news on Deflazacort News trends on Deflazacort
Commentary
Blogs on Deflazacort
Definitions
Definitions of Deflazacort
Patient Resources / Community
Patient resources on Deflazacort Discussion groups on Deflazacort Patient Handouts on Deflazacort Directions to Hospitals Treating Deflazacort Risk calculators and risk factors for Deflazacort
Healthcare Provider Resources
Symptoms of Deflazacort Causes & Risk Factors for Deflazacort Diagnostic studies for Deflazacort Treatment of Deflazacort
Continuing Medical Education (CME)
CME Programs on Deflazacort
International
Deflazacort en Espanol Deflazacort en Francais
Business
Deflazacort in the Marketplace Patents on Deflazacort
Experimental / Informatics
List of terms related to Deflazacort

Deflazacort
Clinical data
AHFS/Drugs.com	International Drug Names
Routes of; administration	Oral
ATC code	H02AB13 (WHO) ;
Pharmacokinetic data
Protein binding	40%
Metabolism	By plasma esterases, to active metabolite
Elimination half-life	1.1–1.9 hours (metabolite)
Excretion	Renal (70%) and fecal (30%)
Identifiers
	IUPAC name (11β,16β)-21-(acetyloxy)-11-hydroxy-2′-methyl-5′H-pregna-1,4-dieno[17,16-d]oxazole-3,20-dione;
CAS Number	14484-47-0 ;
PubChem CID	26709;
ChemSpider	164861 ;
UNII	KR5YZ6AE4B;
KEGG	D03671 ;
ChEMBL	ChEMBL1201891 ;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C25H31NO6
Molar mass	441.517 g/mol
3D model (JSmol)	Interactive image;
	SMILES O=C(OCC(=O)[C@]25/N=C(\O[C@@H]5C[C@H]1[C@H]4[C@H]([C@@H](O)C[C@@]12C)[C@]/3(/C=C\C(=O)\C=C\3CC4)C)C)C;
	InChI InChI=1S/C25H31NO6/c1-13-26-25(20(30)12-31-14(2)27)21(32-13)10-18-17-6-5-15-9-16(28)7-8-23(15,3)22(17)19(29)11-24(18,25)4/h7-9,17-19,21-22,29H,5-6,10-12H2,1-4H3/t17-,18-,19-,21+,22+,23-,24-,25+/m0/s1 ; Key:FBHSPRKOSMHSIF-GRMWVWQJSA-N ;
(what is this?) (verify)

Deflazacort
Clinical data
AHFS/Drugs.com	International Drug Names
Routes of; administration	Oral
ATC code	H02AB13 (WHO) ;
Pharmacokinetic data
Protein binding	40%
Metabolism	By plasma esterases, to active metabolite
Elimination half-life	1.1–1.9 hours (metabolite)
Excretion	Renal (70%) and fecal (30%)
Identifiers
	IUPAC name (11β,16β)-21-(acetyloxy)-11-hydroxy-2′-methyl-5′H-pregna-1,4-dieno[17,16-d]oxazole-3,20-dione;
CAS Number	14484-47-0 ;
PubChem CID	26709;
ChemSpider	164861 ;
UNII	KR5YZ6AE4B;
KEGG	D03671 ;
ChEMBL	ChEMBL1201891 ;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C25H31NO6
Molar mass	441.517 g/mol
3D model (JSmol)	Interactive image;
	SMILES O=C(OCC(=O)[C@]25/N=C(\O[C@@H]5C[C@H]1[C@H]4[C@H]([C@@H](O)C[C@@]12C)[C@]/3(/C=C\C(=O)\C=C\3CC4)C)C)C;
	InChI InChI=1S/C25H31NO6/c1-13-26-25(20(30)12-31-14(2)27)21(32-13)10-18-17-6-5-15-9-16(28)7-8-23(15,3)22(17)19(29)11-24(18,25)4/h7-9,17-19,21-22,29H,5-6,10-12H2,1-4H3/t17-,18-,19-,21+,22+,23-,24-,25+/m0/s1 ; Key:FBHSPRKOSMHSIF-GRMWVWQJSA-N ;
(what is this?) (verify)
Clinical data
AHFS/Drugs.com	International Drug Names
Routes of; administration	Oral
ATC code	H02AB13 (WHO) ;
Pharmacokinetic data
Protein binding	40%
Metabolism	By plasma esterases, to active metabolite
Elimination half-life	1.1–1.9 hours (metabolite)
Excretion	Renal (70%) and fecal (30%)
Identifiers
	IUPAC name (11β,16β)-21-(acetyloxy)-11-hydroxy-2′-methyl-5′H-pregna-1,4-dieno[17,16-d]oxazole-3,20-dione;
CAS Number	14484-47-0 ;
PubChem CID	26709;
ChemSpider	164861 ;
UNII	KR5YZ6AE4B;
KEGG	D03671 ;
ChEMBL	ChEMBL1201891 ;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C25H31NO6
Molar mass	441.517 g/mol
3D model (JSmol)	Interactive image;
	SMILES O=C(OCC(=O)[C@]25/N=C(\O[C@@H]5C[C@H]1[C@H]4[C@H]([C@@H](O)C[C@@]12C)[C@]/3(/C=C\C(=O)\C=C\3CC4)C)C)C;
	InChI InChI=1S/C25H31NO6/c1-13-26-25(20(30)12-31-14(2)27)21(32-13)10-18-17-6-5-15-9-16(28)7-8-23(15,3)22(17)19(29)11-24(18,25)4/h7-9,17-19,21-22,29H,5-6,10-12H2,1-4H3/t17-,18-,19-,21+,22+,23-,24-,25+/m0/s1 ; Key:FBHSPRKOSMHSIF-GRMWVWQJSA-N ;
(what is this?) (verify)

← Older edit Newer edit →

VisualWikitext

Revision as of 18:43, 8 April 2015

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Deflazacort is a glucocorticoid used as an anti-inflammatory and immunosuppressant.

Deflazacort is an inactive prodrug which is metabolized rapidly to the active drug 21-desacetyldeflazacort.^[1] Its potency is around 70–90% that of prednisone.^[2]

It is sold in Bangladesh as Xalcort, marketed by Beacon Pharmaceuticals Limited, in the United Kingdom by Shire under the trade name Calcort;^[2] in Brazil as Cortax, Decortil, and Deflanil; in India as MOAID, Defolet(Roussette), DFZ, Decotaz, and DefZot; in Panama as Zamen, Spain as Zamene and in Honduras as Flezacor.^[3] It is not available in the United States. In January 2015, the FDA granted fast track status to Marathon Pharmaceuticals to pursue approval of deflazacort as a potential treatment for Duchenne muscular dystrophy. The company expects to make deflazacort available in the United States in 2016. ^[4]

References

↑ Möllmann, H; Hochhaus, G; Rohatagi, S; Barth, J; Derendorf, H (1995). "Pharmacokinetic/pharmacodynamic evaluation of deflazacort in comparison to methylprednisolone and prednisolone". Pharmaceutical research. 12 (7): 1096–100. PMID 7494809.
↑ ^2.0 ^2.1 "Calcort". electronic Medicines Compendium. June 11, 2008. Retrieved on October 28, 2008.
↑ "Substâncias: DEFLAZACORT" (in português). Centralx. 2008. Retrieved on October 28, 2008.
↑ http://www.chicagotribune.com/business/ct-marathon-muscular-dystrophy-drug-0119-biz-20150119-story.html#page=1

[1] Möllmann, H; Hochhaus, G; Rohatagi, S; Barth, J; Derendorf, H (1995). "Pharmacokinetic/pharmacodynamic evaluation of deflazacort in comparison to methylprednisolone and prednisolone". Pharmaceutical research. 12 (7): 1096–100. PMID 7494809.

[eMC-2] 2.0 ^2.1 "Calcort". electronic Medicines Compendium. June 11, 2008. Retrieved on October 28, 2008.

[Centralx-3] "Substâncias: DEFLAZACORT" (in português). Centralx. 2008. Retrieved on October 28, 2008.

[4] ttp://www.chicagotribune.com/business/ct-marathon-muscular-dystrophy-drug-0119-biz-20150119-story.html#page=1

[5] Möllmann, H; Hochhaus, G; Rohatagi, S; Barth, J; Derendorf, H (1995). "Pharmacokinetic/pharmacodynamic evaluation of deflazacort in comparison to methylprednisolone and prednisolone". Pharmaceutical research. 12 (7): 1096–100. PMID 7494809.

[eMC-6] 2.0 ^2.1 "Calcort". electronic Medicines Compendium. June 11, 2008. Retrieved on October 28, 2008.

[Centralx-7] "Substâncias: DEFLAZACORT" (in português). Centralx. 2008. Retrieved on October 28, 2008.

[8] ttp://www.chicagotribune.com/business/ct-marathon-muscular-dystrophy-drug-0119-biz-20150119-story.html#page=1

[1]

[2]

[3]

[4]

[1]

[2]

[3]

[4]

@@ Line 1: / Line 1: @@
 {{Drugbox
+| Verifiedfields = changed
+| Watchedfields = changed
+| verifiedrevid = 447631837
+| IUPAC_name = (11β,16β)-21-(acetyloxy)-11-hydroxy-2′-methyl-5′''H''-pregna-1,4-dieno[17,16-''d'']oxazole-3,20-dione
+| image ={{Drugbox
 | Verifiedfields = changed
 | Watchedfields = changed
@@ Line 5: / Line 10: @@
 | IUPAC_name = (11β,16β)-21-(acetyloxy)-11-hydroxy-2′-methyl-5′''H''-pregna-1,4-dieno[17,16-''d'']oxazole-3,20-dione
 | image = Deflazacort structure.png
+<!--Clinical data-->
+| tradename =
+| Drugs.com = {{drugs.com|international|deflazacort}}
+| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
+| pregnancy_US = <!-- A / B            / C / D / X -->
+| pregnancy_category =
+| legal_AU = <!-- Unscheduled / S2 / S3 / S4  / S8 -->
+| legal_UK = <!-- GSL         / P       / POM / CD -->
+| legal_US = <!-- OTC                   / Rx-only  -->
+| legal_status =
+| routes_of_administration = Oral
+<!--Pharmacokinetic data-->
+| bioavailability =
+| protein_bound = 40%
+| metabolism = By plasma [[esterase]]s, to active metabolite
+| elimination_half-life = 1.1–1.9 hours (metabolite)
+| excretion = [[Kidney|Renal]] (70%) and fecal (30%)
+<!--Identifiers-->
+| CAS_number_Ref = {{cascite|correct|??}}
+| CAS_number = 14484-47-0
+| ATC_prefix = H02
+| ATC_suffix = AB13
+| PubChem = 26709
+| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
+| DrugBank =
+| ChEMBL_Ref = {{ebicite|changed|EBI}}
+| ChEMBL = 1201891
+| UNII_Ref = {{fdacite|correct|FDA}}
+| UNII = KR5YZ6AE4B
+| KEGG_Ref = {{keggcite|correct|kegg}}
+| KEGG = D03671
+|  ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
+| ChemSpiderID = 164861
+|  smiles = O=C(OCC(=O)[C@]25/N=C(\O[C@@H]5C[C@H]1[C@H]4[C@H]([C@@H](O)C[C@@]12C)[C@]/3(/C=C\C(=O)\C=C\3CC4)C)C)C
+|  InChI = 1/C25H31NO6/c1-13-26-25(20(30)12-31-14(2)27)21(32-13)10-18-17-6-5-15-9-16(28)7-8-23(15,3)22(17)19(29)11-24(18,25)4/h7-9,17-19,21-22,29H,5-6,10-12H2,1-4H3/t17-,18-,19-,21+,22+,23-,24-,25+/m0/s1
+|  InChIKey = FBHSPRKOSMHSIF-GRMWVWQJBC
+|  StdInChI_Ref = {{stdinchicite|changed|chemspider}}
+| StdInChI = 1S/C25H31NO6/c1-13-26-25(20(30)12-31-14(2)27)21(32-13)10-18-17-6-5-15-9-16(28)7-8-23(15,3)22(17)19(29)11-24(18,25)4/h7-9,17-19,21-22,29H,5-6,10-12H2,1-4H3/t17-,18-,19-,21+,22+,23-,24-,25+/m0/s1
+|  StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
+| StdInChIKey = FBHSPRKOSMHSIF-GRMWVWQJSA-N
+<!--Chemical data-->
+| C=25 | H=31 | N=1 | O=6
+| molecular_weight = 441.517 g/mol
+}}
+'''Deflazacort''' is a [[glucocorticoid]] used as an [[anti-inflammatory]] and [[immunosuppressant]].
+Deflazacort is an inactive [[prodrug]] which is [[drug metabolism|metabolized]] rapidly to the active drug 21-desacetyldeflazacort.<ref>{{cite journal | pmid = 7494809 | year = 1995 | last1 = Möllmann | first1 = H | last2 = Hochhaus | first2 = G | last3 = Rohatagi | first3 = S | last4 = Barth | first4 = J | last5 = Derendorf | first5 = H | title = Pharmacokinetic/pharmacodynamic evaluation of deflazacort in comparison to methylprednisolone and prednisolone | volume = 12 | issue = 7 | pages = 1096–100 | journal = Pharmaceutical research }}</ref> Its potency is around 70–90% that of [[prednisone]].<ref name="eMC"/>
+It is sold in [[Bangladesh]] as Xalcort, marketed by Beacon Pharmaceuticals Limited, in the [[United Kingdom]] by [[Shire plc|Shire]] under the trade name Calcort;<ref name="eMC">{{cite web | url = http://emc.medicines.org.uk/emc/assets/c/html/displaydoc.asp?documentid=20915 | title = Calcort | date = June 11, 2008 | publisher = electronic Medicines Compendium}} Retrieved on October 28, 2008.</ref> in [[Brazil]] as Cortax, Decortil, and Deflanil; in India as MOAID, Defolet(Roussette), DFZ, Decotaz, and DefZot; in Panama as Zamen, Spain as Zamene and in Honduras as Flezacor.<ref name=Centralx>{{cite web | url = http://www.bulas.med.br/index.pl?C=A&V=66506F737449443D39333933266163743D73686F7752656164436F6D6D656E7473<!--convenience link--> | title = Substâncias: DEFLAZACORT | year = 2008 | publisher = Centralx|language=pt}} Retrieved on October 28, 2008.</ref> It is not available in the United States. In January 2015, the FDA granted fast track status to Marathon Pharmaceuticals to pursue approval of deflazacort as a potential treatment for Duchenne muscular dystrophy. The company expects to make deflazacort available in the United States in 2016. <ref>http://www.chicagotribune.com/business/ct-marathon-muscular-dystrophy-drug-0119-biz-20150119-story.html#page=1</ref>
+==References==
+{{Reflist|2}}
+[[Category:Glucocorticoids]]
+[[Category:Prodrugs]]
 <!--Clinical data-->

Deflazacort: Difference between revisions

Revision as of 18:43, 8 April 2015

References

Overview

References

Navigation menu

Search